These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 12725951)

  • 21. Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin.
    Leontyev D; Katsman Y; Ma XZ; Miescher S; Käsermann F; Branch DR
    Transfusion; 2012 Aug; 52(8):1799-805. PubMed ID: 22257295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunoglobulin G dimers and immune complexes are dispensable for the therapeutic efficacy of intravenous immune globulin in murine immune thrombocytopenia.
    Tremblay T; Paré I; Bazin R
    Transfusion; 2013 Feb; 53(2):261-9. PubMed ID: 22670706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of Fcgamma receptors in the pathogenesis and treatment of idiopathic thrombocytopenic purpura.
    Crow AR; Lazarus AH
    J Pediatr Hematol Oncol; 2003 Dec; 25 Suppl 1():S14-8. PubMed ID: 14668633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of childhood acute immune thrombocytopenic purpura with anti-D immune globulin or pooled immune globulin.
    Tarantino MD; Madden RM; Fennewald DL; Patel CC; Bertolone SJ
    J Pediatr; 1999 Jan; 134(1):21-6. PubMed ID: 9880444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous immunoglobulin for autoimmune thrombocytopenic purpura.
    Bierling P; Godeau B
    Hum Immunol; 2005 Apr; 66(4):387-94. PubMed ID: 15866702
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High dose intravenous immunoglobulin repertoire versus anti-D. Disproportions in quantity and quality.
    Rewald E; Francischetti MM; Barberis L
    Cell Mol Biol (Noisy-le-grand); 2002 May; 48(3):265-9. PubMed ID: 12030430
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced efficacy of anti-D immunoglobulin for treating ITP is not explained by higher immunoglobulin polymer content.
    Dolman C; Thorpe SJ; Thorpe R
    Biologicals; 2001 Jun; 29(2):75-9. PubMed ID: 11580212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells.
    Siragam V; Crow AR; Brinc D; Song S; Freedman J; Lazarus AH
    Nat Med; 2006 Jun; 12(6):688-92. PubMed ID: 16715090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravenous immunoglobulin G and anti-D as therapeutic interventions in immune thrombocytopenic purpura.
    Blanchette V; Carcao M
    Transfus Sci; 1998 Sep; 19(3):279-88. PubMed ID: 10351140
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children.
    Tarantino MD; Young G; Bertolone SJ; Kalinyak KA; Shafer FE; Kulkarni R; Weber LC; Davis ML; Lynn H; Nugent DJ;
    J Pediatr; 2006 Apr; 148(4):489-94. PubMed ID: 16647411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A review of anti-D treatment of childhood idiopathic thrombocytopenic purpura.
    Kjaersgaard M; Hasle H
    Pediatr Blood Cancer; 2006 Oct; 47(5 Suppl):717-20. PubMed ID: 16933265
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcgammaRIIa and FcgammaRIIIa polymorphisms.
    Cooper N; Heddle NM; Haas M; Reid ME; Lesser ML; Fleit HB; Woloski BM; Bussel JB
    Br J Haematol; 2004 Feb; 124(4):511-8. PubMed ID: 14984503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia.
    Barsam SJ; Psaila B; Forestier M; Page LK; Sloane PA; Geyer JT; Villarica GO; Ruisi MM; Gernsheimer TB; Beer JH; Bussel JB
    Blood; 2011 May; 117(21):5723-32. PubMed ID: 21389318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparative study of initial use of intravenous immunoglobulin and prednisolone treatments in childhood idiopathic thrombocytopenic purpur.
    Ou CY; Hsieh KS; Chiou YH; Chang YH; Ger LP
    Acta Paediatr Taiwan; 2006; 47(5):226-31. PubMed ID: 17352309
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective evaluation of high-cost management of severe chronic ITP in children and adolescents<16 years.
    ElAlfy MS; Khalifa AS
    Pediatr Blood Cancer; 2006 Oct; 47(5 Suppl):731-3. PubMed ID: 16933268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protective mechanisms of IVIG.
    Clynes R
    Curr Opin Immunol; 2007 Dec; 19(6):646-51. PubMed ID: 18032008
    [No Abstract]   [Full Text] [Related]  

  • 37. Intravenous immunoglobulin and anti-RhD therapy in the management of immune thrombocytopenia.
    Cooper N
    Hematol Oncol Clin North Am; 2009 Dec; 23(6):1317-27. PubMed ID: 19932436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous immunoglobulin does not increase FcgammaRIIB expression on monocytes/macrophages during acute Kawasaki disease.
    Ichiyama T; Ueno Y; Hasegawa M; Ishikawa Y; Matsubara T; Furukawa S
    Rheumatology (Oxford); 2005 Mar; 44(3):314-7. PubMed ID: 15572393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tetramolecular immune complexes are more efficient than IVIg to prevent antibody-dependent in vitro and in vivo phagocytosis of blood cells.
    Bazin R; Lemieux R; Tremblay T; St-Amour I
    Br J Haematol; 2004 Oct; 127(1):90-6. PubMed ID: 15384982
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of adult idiopathic thrombocytopenic purpura.
    Nakhoul IN; Kozuch P; Varma M
    Clin Adv Hematol Oncol; 2006 Feb; 4(2):136-44, 153. PubMed ID: 16728922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.